⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL31307175 | 0.98 | — | — | |
| SCHEMBL2171972 | 0.77 | — | — | |
| SCHEMBL6059492 | 0.75 | — | — | |
| SCHEMBL22412870 | 0.68 | — | — | |
| SCHEMBL2172092 | 0.67 | — | — | |
| SCHEMBL16008544 | 0.65 | — | — | |
| SCHEMBL2172055 | 0.64 | — | — | |
| SCHEMBL3572586 | 0.62 | — | — | |
| SCHEMBL30210650 | 0.61 | — | — | |
| SCHEMBL30210798 | 0.61 | DRD2 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1567527-A1 | CONDENSED PYRAZOLO DERIVATIVES | ELI LILLY AND COMPANY (US) | 2005-08-31 | — | — | EP | claimed |
| WO-2004050659-A1 | NOVEL COMPOUNDS AS PHARMACEUTICAL AGENTS | ELI LILLY AND COMPANY (US) | 2004-06-17 | — | — | WO | claimed |
| US-20250115587-A1 | PYRAZOLE DERIVATIVES AS H4 ANTAGONIST COMPOUNDS | NXERA PHARMA UK LIMITED (GB) | 2025-04-10 | — | — | US | disclosed |
| US-12234227-B2 | Pyrazole derivatives as H4 antagonist compounds | NXERA PHARMA UK LIMITED (GB) | 2025-02-25 | — | — | US | disclosed |
| WO-2023020209-A1 | UREA COMPOUND CONTAINING 2-HETEROAROMATIC RING SUBSTITUTION, PREPARATION METHOD THEREFOR AND USE THEREOF | 中国科学院上海药物研究所 | 2023-02-23 | — | — | WO | disclosed |
| WO-2023280254-A1 | TEAD INHIBITOR | 武汉人福创新药物研发中心有限公司 | 2023-01-12 | — | — | WO | disclosed |
| US-20210300906-A1 | PYRAZOLE DERIVATIVES AS H4 ANTAGONIST COMPOUNDS | NXERA PHARMA UK LIMITED (GB) | 2021-09-30 | — | — | US | disclosed |
| EP-3226690-A1 | NOVEL TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES | Merck Sharp & Dohme Corp. (US) | 2017-10-11 | — | — | EP | disclosed |
| WO-2016089833-A1 | NOVEL TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES | MERCK SHARP & DOHME CORP. (US) | 2016-06-09 | — | — | WO | disclosed |
| US-9314026-B2 | Heterocyclylpyri(mi)dinylpyrazole | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-04-19 | — | — | US | disclosed |
| US-20140364456-A1 | HETEROCYCLYLPYRI(MI)DINYLPYRAZOLE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-12-11 | — | — | US | disclosed |
| US-7585873-B2 | antiserotonine agents; central nervous system disorders; Alzheimer's disease; 3-(Phenylthio)-1H-pyrrolo[2,3-b]pyridine | WYETH (US) | 2009-09-08 | — | — | US | disclosed |
| US-7411064-B2 | 1-Heterocyclylalkyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2008-08-12 | — | — | US | disclosed |
| US-20080070943-A1 | Sulfonyldihydroimidazopyridinone compounds as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2008-03-20 | — | — | US | disclosed |
| US-7297705-B2 | Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2007-11-20 | — | — | US | disclosed |
| US-7291736-B2 | Sulfonyldihydroimidazopyridinone compounds as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2007-11-06 | — | — | US | disclosed |
| US-7241767-B2 | Quinazoline(di)ones for invertebrate pest control | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2007-07-10 | — | — | US | disclosed |
| US-7087626-B2 | Pyrrole derivatives as pharmaceutical agents | ELI LILLY AND COMPANY (US) | 2006-08-08 | — | — | US | disclosed |
| EP-1397364-A1 | NOVEL PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | ELI LILLY AND COMPANY (US) | 2004-03-17 | — | — | EP | disclosed |
| WO-2002094833-A1 | NOVEL PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | ELI LILLY AND COMPANY (US) | 2002-11-28 | — | — | WO | disclosed |